Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in Oregon: - Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
- Providence Willamette Falls Medical Center — Oregon City, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Saint Vincent Medical Center — Portland, Oregon
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Oregon: - Kaiser Permanente Westside Medical Center — Hillsboro, Oregon
- OHSU Knight Cancer Institute Hematology Oncology — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04524871
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Oregon: - USA15-0 — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07291076
Sites in Oregon: - Local Institution - 0080 — Portland, Oregon
- Local Institution - 0111 — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 yea…
Sponsor: Eureka Therapeutics Inc.
NCT ID: NCT04864054
Sites in Oregon: - Oregon Health and Sciences University — Portland, Oregon
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other p…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06811116
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 2 Recruiting Academic/Other
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to nearby tissu…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT05705492
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Oregon: - Exelixis Clinical Site #51 — Portland, Oregon
Phase 1 Recruiting Industry
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…
Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon: - Providence Cancer Institute — Portland, Oregon
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon: - Massive Bio SYNERGY-AI site — Portland, Oregon